Jensen Investment Management Inc. grew its stake in Zimmer Biomet Holdings Inc (NYSE:ZBH) by 11.6% in the 1st quarter, HoldingsChannel.com reports. The institutional investor owned 7,600 shares of the medical equipment provider’s stock after buying an additional 790 shares during the quarter. Jensen Investment Management Inc.’s holdings in Zimmer Biomet were worth $971,000 as of its most recent SEC filing.

Several other institutional investors and hedge funds also recently made changes to their positions in ZBH. Nisa Investment Advisors LLC lifted its stake in Zimmer Biomet by 5.5% in the first quarter. Nisa Investment Advisors LLC now owns 85,539 shares of the medical equipment provider’s stock valued at $10,923,000 after buying an additional 4,496 shares during the last quarter. LaFleur & Godfrey LLC lifted its stake in Zimmer Biomet by 8.8% in the first quarter. LaFleur & Godfrey LLC now owns 36,320 shares of the medical equipment provider’s stock valued at $4,638,000 after buying an additional 2,935 shares during the last quarter. Dubuque Bank & Trust Co. purchased a new stake in Zimmer Biomet in the first quarter valued at approximately $84,000. FNY Investment Advisers LLC purchased a new stake in Zimmer Biomet in the first quarter valued at approximately $54,000. Finally, Aries Wealth Management purchased a new stake in Zimmer Biomet in the first quarter valued at approximately $206,000. Institutional investors and hedge funds own 89.40% of the company’s stock.

Zimmer Biomet stock opened at $115.92 on Tuesday. The company has a current ratio of 2.00, a quick ratio of 0.97 and a debt-to-equity ratio of 0.72. Zimmer Biomet Holdings Inc has a fifty-two week low of $96.99 and a fifty-two week high of $134.55. The firm has a market capitalization of $23.84 billion, a price-to-earnings ratio of 15.17, a PEG ratio of 2.14 and a beta of 1.19.

Zimmer Biomet (NYSE:ZBH) last issued its quarterly earnings data on Friday, April 26th. The medical equipment provider reported $1.87 earnings per share (EPS) for the quarter, beating the Thomson Reuters’ consensus estimate of $1.86 by $0.01. Zimmer Biomet had a positive return on equity of 13.24% and a negative net margin of 3.90%. The business had revenue of $1.98 billion for the quarter, compared to the consensus estimate of $1.97 billion. During the same period in the prior year, the business earned $1.91 earnings per share. The business’s revenue was down 2.1% on a year-over-year basis. Equities analysts predict that Zimmer Biomet Holdings Inc will post 7.81 EPS for the current year.

The firm also recently announced a quarterly dividend, which was paid on Tuesday, April 30th. Investors of record on Friday, March 29th were given a dividend of $0.24 per share. The ex-dividend date was Thursday, March 28th. This represents a $0.96 annualized dividend and a yield of 0.83%. Zimmer Biomet’s dividend payout ratio (DPR) is presently 12.57%.

In other news, Director Syed A. Jafry purchased 1,925 shares of the company’s stock in a transaction on Friday, March 1st. The stock was bought at an average cost of $125.52 per share, for a total transaction of $241,626.00. The purchase was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Corporate insiders own 0.72% of the company’s stock.

A number of research analysts have recently issued reports on ZBH shares. Cantor Fitzgerald set a $135.00 target price on Zimmer Biomet and gave the company a “buy” rating in a report on Friday, April 26th. Zacks Investment Research lowered Zimmer Biomet from a “hold” rating to a “sell” rating in a report on Saturday, April 13th. Barclays set a $113.00 target price on Zimmer Biomet and gave the company a “sell” rating in a report on Tuesday, February 5th. Oppenheimer reissued a “buy” rating on shares of Zimmer Biomet in a report on Saturday, February 2nd. Finally, TheStreet lowered Zimmer Biomet from a “b-” rating to a “c” rating in a report on Friday, February 1st. Four analysts have rated the stock with a sell rating, eight have assigned a hold rating, twelve have given a buy rating and one has given a strong buy rating to the company’s stock. The stock presently has a consensus rating of “Hold” and an average target price of $130.19.

ILLEGAL ACTIVITY WARNING: This news story was originally published by Watch List News and is owned by of Watch List News. If you are accessing this news story on another website, it was copied illegally and republished in violation of US and international copyright and trademark legislation. The correct version of this news story can be viewed at https://www.watchlistnews.com/jensen-investment-management-inc-buys-790-shares-of-zimmer-biomet-holdings-inc-zbh/3017691.html.

Zimmer Biomet Company Profile

Zimmer Biomet Holdings, Inc, together with its subsidiaries, designs, manufactures, and markets musculoskeletal healthcare products and solutions in the Americas, Europe, the Middle East, Africa, and the Asia Pacific. It operates through four segments: Spine, less Asia Pacific; Office Based Technologies; Craniomaxillofacial and Thoracic; and Dental.

Recommended Story: What is a blue-chip stock?

Want to see what other hedge funds are holding ZBH? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Zimmer Biomet Holdings Inc (NYSE:ZBH).

Institutional Ownership by Quarter for Zimmer Biomet (NYSE:ZBH)

Receive News & Ratings for Zimmer Biomet Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Zimmer Biomet and related companies with MarketBeat.com's FREE daily email newsletter.